Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older.
• People who have been diagnosed with a specific type and stage of lung cancer called locally advanced non-small cell lung cancer (NSCLC), confirmed by a laboratory test on a tissue or cell sample, at stage IIIA (not removable by surgery), IIIB, or IIIC.
• People aged 70 or older whose general physical condition is rated as 0 or 1 on a standard medical fitness scale (meaning fully active or able to carry out light work).
• People under 70 whose general physical condition is rated 0 or 1 on the same fitness scale and who also have significant other health conditions, OR whose fitness is rated as 2 on that scale.
• People whose treatment plan — specifically a sequential course of chemotherapy followed by radiotherapy — has been approved by a specialist medical team.
• People whose cancer can be measured using standard imaging criteria (called RECIST 1.1).
• People whose lung function tests show results at or above minimum required levels (confirm with trial site for specific values).
• People whose blood counts (white cells, platelets, and red blood cells) meet minimum required levels (confirm with trial site for specific values).
• People whose kidney and liver function test results meet minimum required levels (confirm with trial site for specific values).
• People who have national health insurance coverage.
• People of childbearing potential, and men who are sexually active with someone who could become pregnant, who agree to use an effective method of contraception during treatment and for 6 months after the last dose.

Who may not be able to join:

• People for whom immunotherapy or chemotherapy is medically unsuitable.
• People whose specialist medical team has approved a treatment plan where chemotherapy and radiotherapy are given at the same time (rather than one after the other).
• People with Stage I or Stage II non-small cell lung cancer.
• People who have previously received immunotherapy or chemotherapy for non-small cell lung cancer.
• People whose lung cancer is not a primary non-small cell lung cancer type.
• People whose tumour has specific genetic changes known as EGFR mutation, or ALK or ROS1 translocations.
• People whose cancer has spread to other parts of the body, including the brain.
• People who are not suitable for radiotherapy aimed at curing the disease, due to the size or position of the tumour.
• People with serious uncontrolled health conditions, such as a recent heart attack (within 3 months), unstable chest pain, severe heart failure, uncontrolled high blood pressure, advanced liver disease, severe infection, or heart muscle inflammation — or any other active condition that would make chemotherapy, immunotherapy, or radiotherapy unsafe.
• People who have lost 15% or more of their total body weight in the last 6 months.
• People whose general physical fitness is rated above 2 on the standard medical fitness scale.
• People with an active autoimmune disease (where the immune system attacks the body), or a history of certain autoimmune conditions such as lupus, inflammatory bowel disease, vasculitis, or others listed in the criteria (confirm with trial site for the full list). Note: autoimmune thyroid conditions managed with replacement therapy, and type 1 diabetes managed with insulin, are generally permitted.
• People with a history of certain lung scarring conditions (such as idiopathic pulmonary fibrosis or organised pneumonia), or signs of active lung inflammation on a scan.
• People who have taken immune-suppressing medications within the past 28 days, or steroid medications above a certain dose within the past 7 days (confirm with trial site for specific details; some exceptions apply).
• People with chronic active infections including tuberculosis, HIV, active hepatitis B, or active hepatitis C (some people with a history of treated hepatitis B or C may still be eligible — confirm with trial site).
• People who have had a severe infection (including COVID-19 requiring hospitalisation) within 4 weeks before starting the study treatment.
• People who have had another cancer within the past 3 years, or have a cancer that is still progressing (except certain skin cancers or non-invasive cervical cancers).
• People who have previously had radiotherapy to the chest area.
• People who have received a live vaccine within 28 days before starting chemotherapy.
• People who have had an organ or bone marrow transplant.
• People who have had major surgery within 4 weeks before starting treatment.
• People who are already taking part in another clinical treatment trial.
• People who are pregnant or breastfeeding.
• People under legal guardianship or curatorship.
• People unable to attend the required study visits or follow the study requirements for geographical, social, or physical reasons.
• People who are unable to understand what the study involves.

Important: Always verify eligibility with the trial site directly before applying.